Actavis' Namenda switch exceeds expectations, and its ability to supply new version

Usually, exceeding expectations when it comes to a sales goal is a good thing. But in the case of Actavis ($ACT) and its forced switch of patients to a once-daily version of its Alzheimer's treatment Namenda, it is posing some problems--supply problems. The company announced earlier that it would stop production in August of the original version, a move that would leave patients no choice but to switch to the patent protected extended release product, and so keep most of the sales. It has since said it will continue to make it into the fall and conceded to Bloomberg that it is having trouble keeping up with demand for the new capsule. Story | More

Suggested Articles

FDA researchers uncover more concerns and fears among front-line workers and minority groups about a COVID-19 vaccine.

Provention Bio wants to connect the familial threads around Type 1 diabetes with two new campaigns—one targeted at doctors and the other at consumers.

Novartis’ latest campaign with a celebrity dance partner asks people to bust a move to raise awareness around sickle cell anemia and therapy Adakveo.